Gout

Metabolic·MeSH: Arthritis, Gouty

Prevalence

756.6 / 100K

Incidence

127.5 / 100K/yr

21 drugs in development·15 companies·5 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
colchicine	Mylan II B.V. (MYL)
Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)
gloperba	SCILEX HOLDING CO (SCLX)
indocin	Zyla Life Sciences (ZCOR)
indocin	Assertio Holdings, Inc. (ASRT)
INDOCIN (suppositories and oral suspension)	Assertio Holdings, Inc. (ASRT)
INDOCIN Oral Suspension	Assertio Holdings, Inc. (ASRT)
indomethacin	Mylan II B.V. (MYL)
indomethacin	Amneal Pharmaceuticals, Inc. (AMRX)
krystexxa	Horizon Therapeutics Public Ltd Co (HZNP)
Purified Cortrophin Gel	ANI PHARMACEUTICALS INC (ANIP)

Phase 3(2)

Drug	Company
pegloticase	AMGEN INC (AMGN)
qingzhu granules	NYMOX PHARMACEUTICAL CORP (NYMXF)

Phase 1(3)

Drug	Company
hec93077	SUNSHINE BIOPHARMA INC. (SBFM)
prx-115	Protalix BioTherapeutics, Inc. (PLX)
sibp-r002	CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (CBPO)

Preclinical(3)

Drug	Company
alln-346	Allena Pharmaceuticals, Inc. (ALNA)
Phyto-N	Curanex Pharmaceuticals Inc (CURX)
synb2081	SYNLOGIC, INC. (SYBX)

Phase 4(2)

Drug	Company
Purified Cortophin Gel 80 U	ANI PHARMACEUTICALS INC (ANIP)
Purified Cortophin Gel, 40 U	ANI PHARMACEUTICALS INC (ANIP)

BioSniper tracks 21 drugs in development for Gout across 15 companies.

There are 5 clinical trials targeting Gout tracked by BioSniper.

The estimated prevalence of Gout is approximately 756.6 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.